Immunome Stock News

The FDA has lifted the clinical hold on Immunome Inc''s (NASDAQ: IMNM ) Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) to treat COVID-19. Immunome previously announced that the FDA had placed its IND application on clinical hold due to a request for … Full story available on Benzinga.com

Immunome (IMNM) said the U.S. Food and Drug Administration ((FDA)) lifted a clinical hold on its investigational new drug ((IND)) application to begin a trial of antibody…

Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more

Immunome Inc (NASDAQ: IMNM ) shares rose before falling after reporting results from testing its experimental three-antibody cocktail against live versions of the COVID-19 omicron variant . CEO Purnanand Sarma said that there had been a significant reduction in the number of antibody therapeutics under emergency use authorization that are active against omicron in recent weeks. That trend, he said, demonstrates … Full story available on Benzinga.com

Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-antibody cocktail against live versions of the COVID-19 omicron variant. Get the Inside Acces

Immunome (IMNM) said in vitro data showed effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid…

Immunome Inc (NASDAQ: IMNM) has received an FDA clinical hold letter in response to its recently submitted IND requesting further information related to the preparation and administration of IMM-BC

Immunome (IMNM) shares sink 18% in aftermarket trade after it said it received a clinical hold letter from the FDA for IMM-BCP-01, a three-antibody cocktail for the treatment

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that members of management will participate in a fireside chat hosted by Cantor Fitzgerald Analyst Brian Cheng on Wednesday, December 8, 2021 at 1:00 p.m. ET. The live call is reserved for institutional clients of Cantor Fitzgerald. A replay of the webcast can be accessed from the Inve

The stock price of Immunome Inc (NASDAQ: IMNM) increased by 12.55% in the most recent trading session. This is why it happened.

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19). I am thrilled that Immunome has submitted its first IND, which is another milestone